In short
Fenfluramine hydrochloride, also known as ZX008 or Fintepla, is emerging as a potential treatment for rare and severe forms of epilepsy, particularly in children and young adults. This article explores the ongoing clinical trials investigating the efficacy and safety of fenfluramine hydrochloride in conditions such as Dravet syndrome, Lennox-Gastaut syndrome, and other epileptic encephalopathies. These studies aim to provide new hope for patients with difficult-to-treat seizure disorders.
At a glance
- Drug Name
- Fenfluramine Hydrochloride (ZX008, Fintepla)
- Primary Conditions Studied
- Dravet syndrome, Lennox-Gastaut syndrome, Epileptic encephalopathies
- Administration
- Oral solution, typically twice daily
- Dosage Range
- 0.2 mg/kg/day to 0.8 mg/kg/day, maximum 30 mg/day (lower when combined with stiripentol)
- Primary Outcome Measures
- Reduction in seizure frequency, safety and tolerability
- Secondary Outcome Measures
- Quality of life, cognitive function, behavior, EEG patterns
- Safety Monitoring
- Echocardiograms, body weight, neurological exams, laboratory tests
- Age Groups Studied
- Varies by trial; includes children, adolescents, and adults
- Study Designs
- Open-label, randomized controlled trials, expanded access programs
- Treatment Duration
- Ranges from 12 weeks to 36 months in different trials
What is Fenfluramine Hydrochloride?
Fenfluramine hydrochloride is a medication being studied for the treatment of rare epilepsy disorders. It is also known by the brand name Fintepla and the research code ZX008. Fenfluramine comes as a clear, cherry-flavored oral solution.
What Conditions Does Fenfluramine Treat?
Fenfluramine is primarily being studied to treat the following rare epilepsy conditions:
- Dravet syndrome: A severe form of epilepsy that begins in infancy and causes frequent, prolonged seizures
- Lennox-Gastaut syndrome: Another severe form of epilepsy that causes multiple types of seizures and intellectual disability
- Sunflower syndrome: A rare epilepsy disorder characterized by seizures triggered by bright light
- Infantile spasms: A type of seizure that occurs in young children
How Does Fenfluramine Work?
Fenfluramine works in two main ways to help control seizures:
- It stimulates the release of serotonin in the brain. Serotonin is a neurotransmitter (brain chemical) that can help reduce seizure activity.
- It activates sigma-1 receptors in the brain, which may also help prevent seizures.
This unique mechanism of action makes fenfluramine different from many other anti-seizure medications.
How is Fenfluramine Administered?
Fenfluramine is given as an oral solution (liquid medicine taken by mouth). The dose is usually divided into two daily doses, taken in the morning and evening. The exact dose depends on factors like:
- The patient's weight
- The specific condition being treated
- Other medications the patient is taking
For example, in some studies, the maximum dose was 0.7 mg/kg/day up to 26 mg/day. For patients also taking a medication called stiripentol, the maximum dose was lower - 0.4 mg/kg/day up to 17 mg/day.
How Effective is Fenfluramine?
Early research shows promising results for fenfluramine in treating rare epilepsies:
- In one study of patients with Dravet syndrome, fenfluramine reduced convulsive seizures by 74.9% compared to 19.2% in the placebo group. Additionally, 16% of children treated with fenfluramine became seizure-free.
- For Sunflower syndrome, the goal is to reduce seizures by 30% or more.
- Studies are also looking at improvements in cognitive function, behavior, and quality of life for patients taking fenfluramine.
Safety and Side Effects
As with any medication, fenfluramine can cause side effects. Researchers are carefully monitoring patients for:
- Changes in heart function, including heart valve problems
- Changes in blood pressure and heart rate
- Effects on growth (height and weight)
- Changes in mood or behavior
- Other potential side effects
Long-term safety studies are ongoing to better understand the risks and benefits of fenfluramine.
Ongoing Research
Several clinical trials are currently studying fenfluramine for various purposes:
- Testing its use in very young children (under 2 years old) with Dravet syndrome
- Evaluating its long-term safety and effectiveness
- Investigating its potential effects on cognitive function in healthy volunteers
- Studying its use in adult patients with Dravet syndrome
These ongoing studies will help researchers better understand how fenfluramine can be used safely and effectively to treat rare epilepsy disorders.